Latest news with #HamletBioPharma
South China Morning Post
26-02-2025
- Health
- South China Morning Post
Breast milk proteins show even more promise against bladder cancer, cystitis in new trials
A potential cancer cure that uses a replica of a protein found in human breast milk has even greater results when given in higher doses, new clinical trials show. Advertisement Alpha1H is a drug synthesised from alpha-lactalbumin, the most common protein in human breast milk, bound to a fatty acid known as oleic acid. In a recent study, it showed complete or partial response in triggering rapid tumour-cell death in 88 per cent of early-stage bladder cancer tumours. It was developed by Hamlet BioPharma, headed by Swedish professor Catharina Svanborg of Lund University Sweden, who made the accidental discovery of the breast milk molecule's cancer-fighting potential in 1995 There were more than 610,000 new bladder cancer cases and more than 220,000 deaths globally in 2022, according to the World Cancer Research Fund. China had the highest number of new cases, at more than 92,000, and 41,000 deaths. Bladder cancer has a high recurrence rate and there is no cure. Professor Catharina Svanborg of Lund University Sweden discovered the potential of breast milk in the fight against cancer in 1995. Photo: Catharina Svanborg 'We are looking at how to alleviate the situation for bladder cancer patients with newly diagnosed cancer, and how to hopefully prevent the tumour from getting worse and how to make surgery easier,' Svanborg says. Advertisement The breast-milk protein used in Alpha1H 'is a very interesting molecule because it's broadly active against many different types of tumour cells. So in a future scenario, we are hoping that it could be helpful for many different types of cancer.'
Yahoo
24-02-2025
- Business
- Yahoo
February 2025's Top Penny Stocks To Watch
As global markets grapple with geopolitical tensions and consumer spending concerns, major U.S. indices have experienced volatility, with the S&P 500 reaching record highs before retreating due to various economic pressures. In such fluctuating conditions, investors often seek opportunities in diverse sectors, including penny stocks—a term that may seem outdated but still holds relevance for those interested in smaller or newer companies. These stocks can offer growth potential at lower price points when backed by strong financials and solid fundamentals, making them an intriguing option for investors looking to uncover hidden gems amidst market uncertainties. Name Share Price Market Cap Financial Health Rating DXN Holdings Bhd (KLSE:DXN) MYR0.515 MYR2.56B ★★★★★★ Datasonic Group Berhad (KLSE:DSONIC) MYR0.32 MYR890.29M ★★★★★★ Bosideng International Holdings (SEHK:3998) HK$3.86 HK$44.31B ★★★★★★ T.A.C. Consumer (SET:TACC) THB4.22 THB2.53B ★★★★★★ Warpaint London (AIM:W7L) £4.00 £323.15M ★★★★★★ Hil Industries Berhad (KLSE:HIL) MYR0.855 MYR283.81M ★★★★★★ Foresight Group Holdings (LSE:FSG) £4.00 £455.98M ★★★★★★ Next 15 Group (AIM:NFG) £3.185 £316.77M ★★★★☆☆ Embark Early Education (ASX:EVO) A$0.795 A$145.87M ★★★★☆☆ Polar Capital Holdings (AIM:POLR) £4.865 £468.97M ★★★★★★ Click here to see the full list of 5,705 stocks from our Penny Stocks screener. Underneath we present a selection of stocks filtered out by our screen. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Hamlet BioPharma AB (publ) is a Swedish company focused on developing drugs for cancer treatment and prevention, with a market cap of SEK687.64 million. Operations: No revenue segments are reported for Hamlet BioPharma. Market Cap: SEK687.64M Hamlet BioPharma is a pre-revenue company in the biotech sector, with a market cap of SEK687.64 million and no significant revenue streams. The company faces financial challenges with less than a year of cash runway and has reported increasing losses over the past five years. Recent executive changes include Catharina Svanborg's appointment as CEO, which may impact strategic direction. Despite being debt-free and having experienced board members, Hamlet BioPharma's share price remains highly volatile, reflecting investor uncertainty amid ongoing drug development efforts and recent follow-on equity offerings to raise SEK26.79 million for operational funding. Unlock comprehensive insights into our analysis of Hamlet BioPharma stock in this financial health report. Explore historical data to track Hamlet BioPharma's performance over time in our past results report. Simply Wall St Financial Health Rating: ★★★★★★ Overview: TradeGo FinTech Limited is an investment holding company that offers integrated securities trading platform services to brokerage firms and their clients in Hong Kong and the People's Republic of China, with a market cap of HK$188.01 million. Operations: The company's revenue is derived from services in Hong Kong, contributing HK$55.96 million, and the People's Republic of China, contributing HK$14.00 million. Market Cap: HK$188.01M TradeGo FinTech Limited, with a market cap of HK$188.01 million, has integrated the DeepSeek-R1 model to enhance its smart trading services, potentially boosting its competitive edge in fintech. Despite stable weekly volatility and a debt-free status, the company faces challenges such as declining profit margins (currently 7.5% from 21.3% last year) and negative earnings growth (-69.8%) over the past year compared to industry averages. However, TradeGo's short-term assets significantly exceed liabilities, providing some financial stability amid these hurdles as it trades below estimated fair value by 47.3%. Click to explore a detailed breakdown of our findings in TradeGo FinTech's financial health report. Gain insights into TradeGo FinTech's past trends and performance with our report on the company's historical track record. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Buriram Sugar Public Company Limited, along with its subsidiaries, is involved in the production and distribution of sugar and molasses both in Thailand and internationally, with a market cap of THB3.72 billion. Operations: The company generates revenue from three main segments: THB6.18 billion from sugar and molasses production and distribution, THB1.06 billion from agricultural product distribution, and THB851 million from electricity and steam production and distribution. Market Cap: THB3.72B Buriram Sugar Public Company Limited, with a market cap of THB3.72 billion, has shown impressive earnings growth of 336.1% over the past year, surpassing industry averages. Despite its high net debt to equity ratio of 90.5%, the company's interest payments are well covered by EBIT at 9.2 times coverage and operating cash flow effectively covers debt at 20.2%. The management and board are experienced with average tenures of six and twelve years respectively, ensuring stability in leadership amidst recent executive changes. Trading below fair value by 16.3%, Buriram Sugar demonstrates both growth potential and financial challenges typical for stocks in this category. Jump into the full analysis health report here for a deeper understanding of Buriram Sugar. Review our historical performance report to gain insights into Buriram Sugar's track record. Embark on your investment journey to our 5,705 Penny Stocks selection here. Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments. Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Jump on the AI train with fast growing tech companies forging a new era of innovation. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NGM:HAMLET B SEHK:8017 and SET:BRR. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
